bromodomain


Also found in: Wikipedia.

bromodomain

A 110-amino acid protein domain which recognises acetylated lysine residues on the N-terminal tails of histone. It is present in over 100 proteins, especially chromatin-associated proteins—e.g., gnc5, peregrin, Snf2, tafii-250.
References in periodicals archive ?
BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes.
Now, a study led by researchers at Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute is the first to demonstrate that BET bromodomain-containing proteins help execute this global inflammatory program in the endothelium while BET bromodomain inhibition can significantly decrease atherosclerosis in vivo.
The Brd2 gene is a member of the Bromodomain Extra Terminal (BET) family of proteins and is closely related to Brd4, which is important in highly lethal carcinomas in young people, as well as in the replication of Human Immunodeficiency Virus (HIV).
He told Matzuk that he was testing JQ1 as an inhibitor of a member of a family of bromodomain proteins, and he was curious to know whether JQ1 would have an effect on a spermatogenic-specific member of the family called BRDT.
BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15; 19).
The bromodomain protein GTE6 controls leaf development in Arabidopsis by histone acetylation at ASYMMETRIC LEAVES1.
7] Human genes: FMR1, fragile X mental retardation 1; AP1S2, adaptor-related protein complex 1, sigma 2 subunit; CUL4B, cullin 4B; BRWD3, bromodomain and WD repeat domain containing 3; UPF3B, UPF3 regulator of nonsense transcripts homolog B (yeast); ZDHHC9, zinc finger, DHHC-type containing 9; SLC9A6, solute carrier family 9 (sodium/hydrogen exchanger), member 6; SYP, synaptophysin; ZNF711, zinc finger protein 711; CASK, calcium/calmodulin-dependent serine protein kinase (MAGUK family).
It has a bromodomain as found in other HATs like Gcn5 and PCAF.
Small molecule inhibition of the bromodomain and extra-terminal - or BET - family of chromatin adaptors produces selective effects on gene expression and leads to the death of tumor cells across a broad range of hematologic malignancies and in subsets of solid tumors, making it a promising new therapeutic approach in oncology.
Johann for guiding Zenith from its initial days as a newly-incorporated company to today as we embark on our investigational new drug application (IND) for our lead BET bromodomain inhibitor in oncology.
is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease.
signed the agreement for specific compounds targeting bromodomain and extra-terminal (BET) proteins for potential use in oncology and other disease areas.